Business / Finance

RSS

Benitec prices initial public offering of 1,500,000 American Depositary Shares

Benitec Biopharma Limited, a clinical-stage biotechnology company, is pleased to announce the pricing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs), representing 30,000,000 fully paid ordinary shares of Benitec and warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares, at a price of US$9.21 per ADS and US$0.01 per warrant.

18 Aug 2015

BioElectronics reports Q2 financial results, publishes market surveys of ActiPatch Therapy

BioElectronics Corporation, the maker of advanced drug-free consumer medical devices, today published on its second quarter financial results along with a market analysis of its long term follow up surveys of customers who are managing pain with ActiPatch Therapy.

18 Aug 2015

Hi-Tech acquires LG Sciences brand of Sports Nutrition and Bodybuilding products

Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition, Weight loss products, and Contract Manufacturing services, and LG Sciences, one of the premier Sports Nutrition and Bodybuilding brands in the United States, today announced that Hi-Tech has acquired LG Sciences brand of Sports Nutrition products and Bodybuilding products.

18 Aug 2015

Genalyte completes $44 million in Series C Financing round

Genalyte, Inc. announced today it has completed a Series C Financing round of $44 million, led by Khosla Ventures. The company is redefining diagnostics with a testing platform and microchip technology that can be utilized in physician offices. With the application of a single drop of blood to a silicon microchip, Genalyte's Maverick Detection System can offer a complete panel of diagnostic test results in fifteen minutes.

18 Aug 2015

Kuros Biosurgery closes financing round of CHF15M

Kuros Biosurgery AG, a biotechnology company developing novel biomaterials and bioactive-biomaterial combination products and focused in therapeutic areas covering sealants and orthobiologics, announced today that it has closed a financing round of CHF15M. An additional investment is expected in a second closing later this year.

18 Aug 2015

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced an increase in funding of up to CDN$287,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support an ongoing research project.

17 Aug 2015

NBTY signs agreement to acquire Dr. Organic

NBTY, Inc., a global leader in vitamins, nutritional supplements and sports nutrition, today announced that it has entered into an agreement to acquire Dr. Organic, a leading naturally inspired skincare line in the UK. The deal is subject to customary closing conditions, and is expected to close later this year.

17 Aug 2015

Bionik Laboratories reports net loss for second quarter 2015

Bionik Laboratories Corp., a pioneering medical device and robotics company developing technologies and solutions for individuals with neurological disorders, announced today its financial results for the quarter ended June 30, 2015.

17 Aug 2015

ADM Tronics' revenues up 69% in first quarter of fiscal year 2016

ADM Tronics Unlimited, Inc., a technology-based developer and manufacturer of innovative technologies and products, today announced results for its first quarter ended June 30, 2016 of Fiscal Year 2016.

14 Aug 2015

PTC Therapeutics closes $150 million of convertible senior notes

PTC Therapeutics, Inc. announced today the closing of its previously announced private offering of $150 million in aggregate principal amount of its convertible senior notes due 2022 (the "Notes"), including the full exercise by the initial purchasers of an option to purchase an additional $25 million in aggregate principal amount of the Notes.

14 Aug 2015

Cord Blood America’s 2015 second quarter revenue increases 39.0% to $1.41 million

Cord Blood America, Inc. today announced financial results for the second quarter ended June 30, 2015.

14 Aug 2015

CASI reports financial results for second quarter 2015

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, today reported financial results for the three and six months ended June 30, 2015.

14 Aug 2015

China Pharma Holdings revenue decreases 7.4% to $5.7 million in Q2 2015

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended June 30, 2015.

14 Aug 2015

WuXi PharmaTech signs definitive and merger agreements

WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with New WuXi Life Science Limited ("Parent") and WuXi Merger Limited ("Merger Sub"), a wholly owned subsidiary of Parent.

14 Aug 2015

Nutrastar's net revenue increases 1.8% to $13.24 million in second quarter 2015

Nutrastar International Inc., a leading producer and supplier of premium branded consumer products, including commercially cultivated Cordyceps Militaris ("Cordyceps"), functional health beverages and organic and specialty foods, today announced its results for the three months and six months ended June 30, 2015.

13 Aug 2015

Rhythm Metabolic completes $40 million Series A financing

Rhythm announced today the completion of a $40 million Series A financing for its subsidiary, Rhythm Metabolic, Inc., which is developing setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway.

13 Aug 2015

Dipexium reports net loss of $4.0 million for second quarter 2015

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended June 30, 2015.

13 Aug 2015

CrystalGenomics signs agreement with Dong-A ST for commercialization of Acelex (polmacoxib) in Korea

CrystalGenomics, Inc. has announced that it has signed a Sales and Marketing Agreement with Dong-A ST Co., Ltd. for the commercialization of Acelex (polmacoxib) in Korea.

13 Aug 2015

Lucideon acquires second Dynamic Secondary Ion Mass Spectrometer

Lucideon is pleased to announce the acquisition of a second Dynamic Secondary Ion Mass Spectrometer (DSIMS). The investment doubles the capacity for DSIMS analysis at Lucideon and represents a response to the demand for the service and Lucideon’s commitment to satisfying customer requirements.

From Lucideon 12 Aug 2015

Imprimis, Advanced Dosage sign license agreement for proprietary compounded ophthalmic formulations

Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced that it has entered into a license agreement with Advanced Dosage Forms, Inc. to expand Imprimis' proprietary ophthalmic injectable and combination topical compounded formulations into Canada. Under the agreement, the licensee has the rights to formulate, market and sell these formulations across Canada.

12 Aug 2015